Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

02 janv. 2018 09h16 HE | Source: Genmab A/S

Genmab to Present at the 36th Annual J.P. Morgan Healthcare Conference

Media Release Copenhagen, Denmark; January 2, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 36th Annual...
21 déc. 2017 08h27 HE | Source: Genmab A/S

Selskabsvedtægter for Genmab A/S

Selskabsvedtægter for Genmab A/S dateret den 15. december 2017 er blevet offentliggjort. Selskabsvedtægterne er tilgængelige på Genmabs hjemmeside:...
21 déc. 2017 08h27 HE | Source: Genmab A/S

Articles of Association for Genmab A/S

Genmab A/S has published its Articles of Association dated December 15, 2017. The Articles of Association can be found on Genmab’s website: http://ir.genmab.com/releases.cfm Contact: Rachel...
15 déc. 2017 13h52 HE | Source: Genmab A/S

Grant of Restricted Stock Units to Board Members, Management and Employees and Grant of Warrants to Management and Employees in Genmab

Company Announcement Copenhagen, Denmark; December 15, 2017 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that at a board meeting the board decided to grant 49,680 restricted stock units...
11 déc. 2017 06h39 HE | Source: Genmab A/S

Genmab’s 2017 R&D Update

Media Release R&D Update to be held today in Atlanta, Georgia Key Opinion Leaders to discuss daratumumab and tisotumab vedotin data Discussion of Genmab’s pipeline, 2017 progress...
04 déc. 2017 11h01 HE | Source: Genmab A/S

Genmab to Hold 2017 R&D Update

Media Release R&D Update to be held live in Atlanta, Georgia Key Opinion Leaders to discuss daratumumab and tisotumab vedotin data Discussion of Genmab’s pipeline, 2017 progress...
29 nov. 2017 15h41 HE | Source: Genmab A/S

Genmab Achieves USD 20 Million Milestone in Daratumumab Collaboration with Janssen and Updates Financial Guidance

Company Announcement Genmab to receive USD 20 million milestone payment from Janssen Milestone triggered by progress in the Phase III study of daratumumab in combination with...
21 nov. 2017 11h12 HE | Source: Genmab A/S

Genmab Announces Submission of Supplemental Biologics License Application to FDA for Daratumumab in Front Line Multiple Myeloma

Company Announcement sBLA submitted to U.S. FDA for daratumumab in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma...
21 nov. 2017 09h34 HE | Source: Genmab A/S

Data from Phase III ALCYONE Study of Daratumumab Accepted for Oral Presentation at Annual Meeting of the American Society of Hematology

Media Release Late-breaking abstract accepted for oral presentation Data from Phase III ALCYONE study of daratumumab in combination with bortezomib, melphalan and prednisone in front line...
21 nov. 2017 06h58 HE | Source: Genmab A/S

Genmab Announces European Regulatory Submission for Daratumumab in Front Line Multiple Myeloma

Company Announcement Application to broaden label for daratumumab in front line multiple myeloma submitted to EMA Submission based on data from Phase III ALCYONE study Genmab to...

Page précédente

Page suivante